MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NTRA stock logo

NTRA

Natera, Inc.

$207.98
4.77
 (2.35%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  29.477B
Shares Outstanding:  3.126M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Steven Leonard Chapman
Full Time Employees:  4424
Address: 
13011 McCallen Pass Building A
Austin
CA
78753
US
Website:  https://www.natera.com
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/08 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,082,5711,696,9112,306,113
Gross Profit492,7401,023,1581,495,486
EBITDA-383,276-148,078-264,020
Operating Income-446,245-222,294-309,911
Net Income-434,801-190,426-208,160

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,441,6991,660,7352,398,344
Total Liabilities676,372465,315685,931
Total Stockholders Equity765,3271,195,4201,712,413
Total Debt441,993187,118198,796
Cash and Cash Equivalents642,095945,5871,076,140

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-246,955135,664215,301
Capital Expenditure-39,199-66,423-106,188
Free Cash Flow-286,15469,241109,113
Net Income-434,801-190,426-208,160
Net Change in Cash176,004303,492130,553

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)4,939,389.498Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)5,156,525.318Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)5,028,866.267Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-1,955,205.496Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-1,872,873.863Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-1,906,800.870Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)572,074.848Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)604,946.678Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)585,621.165Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,074,328.199Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,209,475.827Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,130,019.485Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)4.280Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)4.420Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)4.180Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.697B  ?P/S
 (TTM)
: 
12.81
?Net Income
 (TTM)
: 
-190426000  ?P/E
 (TTM)
: 
-136.88
?Enterprise Value
 (TTM)
: 
28.675B  ?EV/FCF
 (TTM)
: 
296.8
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.15  ?ROIC
 (TTM)
: 
-0.11
?Net Debt
 (TTM)
: 
-781158000  ?Debt/Equity
 (TTM)
: 
0.13
?P/B
 (TTM)
: 
16.64  ?Current Ratio
 (TTM)
: 
3.39

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates NTRA intrinsic value between $7.83 – $8.17 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate NTRA Intrinsic Value

Common questions about NTRA valuation

Is Natera, Inc. (NTRA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Natera, Inc. (NTRA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NTRA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NTRA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NTRA’s P/E ratio?

You can see NTRA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NTRA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NTRA a good long-term investment?

Whether NTRA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

NTRA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

2.35
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 125.38   Year High: 256.36
Price Avg 50: 208.67   Price Avg 200: 192.67
Volume: 1.28M   Average Volume: 1.246M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
31-03-2026 12:48
Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
04-03-2026 12:42
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
26-02-2026 21:37
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
17-02-2026 09:00
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
05-01-2026 19:25
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
Medical Stock Hovers Near Buy Point After 46% Gain
30-12-2025 13:49
Medical Stock Hovers Near Buy Point After 46% Gain

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read